Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2014. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing details the Company's issued share capital as of August 31, 2014:
- Total Issued Ordinary Shares: 5,351,778,639 (25p each)
- Treasury Shares: 502,139,179
- Total Voting Rights: 4,849,639,460
This figure is provided to assist shareholders in calculating notification thresholds under the Financial Conduct Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of voting rights (4,849,639,460) against the latest share register to ensure accurate calculation of disclosure thresholds.
- Confirm the number of shares held in Treasury (502,139,179) as these do not carry voting rights.
- Note that this filing does not contain operational or financial performance updates for the period.